Todd Golub has been named to the scientific advisory board of Ardais of Lexington, Mass. Golub is director for cancer genomics at the Whitehead/MIT Center for Genome Research, and pediatric oncologist at Dana-Farber Cancer Institute. Golub has an MD from the University of Chicago Pritzker School of Medicine and is an investigator with the Howard Hughes Medical Institute.
Jutta Heim and Olli Kallioniemi have joined the scientific advisory board of
PamGene
, a Dutch microarray technology startup. Heim heads the lead discovery center of
Novartis. Kallioniemi
is professor of medical biotechnology at the VTT Technical Research Center of Finland. Previously, he was head of the translational genomics branch at the National Human Genome Research Institute at NIH.
Achim Feurer, 40, has been named director of medicinal chemistry for Heidelberg, Germany-based Graffinity Pharmaceuticals. Feurer was project manager for the medicinal chemistry department of the pharmaceutical unit of Bayer in Wuppertal, Germany. Graffinity combines microarrays and label-free detection systems to assay compound-protein interactions.
Curt LaBelle joins the health care venture capital firm Tullis-Dickerson & Co. of Greenwich, Conn., as senior associate. LaBelle was previously at Convergent Ventures of Los Angeles. LaBelle has an MD/MBA from Columbia University and a BS in economics from Brigham Young University.
Agilent Technologies created a new scientific advisory board and appointed: Paul Herring, director of corporate research at Novartis International; Anthony Martin, president and CEO of Molecular Probes; Mark Skolnick, founder of Myriad Genetics; and Wendell Wierenga, CEO of Syrrx.
Mary Callan, former director of business development at Exelixis, has been appointed vice president of business development at Morphotek of Philadelphia.